ARS Pharmaceuticals, Inc. Class Action Lawsuit
Company: ARS Pharmaceuticals, Inc.
Ticker: (NASDAQ) SPRY
Class Action Period: March 9, 2026 - June 24, 2026
See If You Qualify For Monetary Reward
Join the ARS Pharmaceuticals, Inc. Class Action Lawsuit
CLASS ACTION PERIOD
March 9, 2026 - June 24, 2026
Allegations
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. On June 24, 2026, after the market closed, ARS published a press release announcing that the Company did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, investors and analysts reacted immediately to ARS’s revelation. The price of ARS’s common stock declined from a closing market price of $10.54 per share on June 24, 2026 to $8.02 per share on June 25, 2026, a decline of over 23.9% in the span of just a single day.
Eligibility
To be eligible for the lawsuit, you must have experienced a loss on ARS Pharmaceuticals shares purchased within the class period specified above.
Lead Plaintiff Deadline
If you suffered a loss in ARS Pharmaceuticals during the relevant time frame or pursuant to the relevant offering(s), you have until October 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Frequently Asked Questions
- How can ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) investors check whether their transactions may be relevant?
Investors who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) during the class period (March 9, 2026 - June 24, 2026) may submit their transaction details through this case page.
- Ensure your purchase falls within the class period
- Provide basic transaction and loss details
- Submit your information before the deadline
The lead plaintiff deadline for this case is October 5, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
- Who is eligible for the ARS Pharmaceuticals, Inc. lawsuit?
Anyone who bought shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) during March 9, 2026 - June 24, 2026 and suffered financial losses may be eligible.
- What is the lead plaintiff deadline to join the ARS Pharmaceuticals, Inc. case?
The lead plaintiff deadline for the ARS Pharmaceuticals, Inc. lawsuit is October 5, 2026. Investors who wish to seek appointment as lead plaintiff should act quickly to avoid missing this deadline. No action is required before that date to remain an absent class member.
- What is the class period for ARS Pharmaceuticals, Inc.?
The class period for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is March 9, 2026 - June 24, 2026, during which investors may have been affected by alleged misconduct.
- Could I still be eligible for the ARS Pharmaceuticals, Inc. lawsuit if I sold my shares?
Yes. Investors who purchased ARS Pharmaceuticals, Inc. shares during March 9, 2026 - June 24, 2026 may still qualify, even if they sold their shares later.
- How much compensation can I receive from the ARS Pharmaceuticals, Inc. lawsuit?
Compensation depends on the total losses and the final settlement. Eligible investors in the ARS Pharmaceuticals, Inc. case may receive a portion of the recovery.
- Do I need to pay to participate in the ARS Pharmaceuticals, Inc. case?
No. Most securities fraud cases are handled on a contingency basis, meaning there are generally no upfront attorney’s fees, and attorney’s fees are collected only if there is a recovery.
- Will I need to appear in court for the ARS Pharmaceuticals, Inc. lawsuit?
In most cases, investors do not need to appear in court. The legal team manages the ARS Pharmaceuticals, Inc. case on behalf of participants.
- What documents are required for the ARS Pharmaceuticals, Inc. lawsuit?
To participate in the ARS Pharmaceuticals, Inc. lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.
- What happens after I submit my trade information for ARS Pharmaceuticals, Inc.?
After submission, your details for the ARS Pharmaceuticals, Inc. case will be reviewed, and you may be contacted regarding eligibility or next steps.
- Is this legal advice for the ARS Pharmaceuticals, Inc. lawsuit?
No, this page provides information about the ARS Pharmaceuticals, Inc. case and does not constitute legal advice or create an attorney-client relationship.
- Why should I act quickly on the ARS Pharmaceuticals, Inc. case?
The lead plaintiff deadline for the ARS Pharmaceuticals, Inc. lawsuit is October 5, 2026. Investors who wish to seek appointment as lead plaintiff must apply by that date.
EXPLORE MORE CASES
Peabody Energy Corporation
BTU
Peabody Energy Corporation (BTU) Securities Class Action Lawsuit Update
Lead Plaintiff Deadline: August 24, 2026
Class Period: October 14, 2024 - May 4, 2026
Embecta Corp.
EMBC
Embecta Corp. (EMBC) Securities Class Action Lawsuit Update
Lead Plaintiff Deadline: August 17, 2026
Class Period: November 25, 2025 - May 4, 2026